Strategic partnerships Innovent has active collaboration with global players such as Eli Lilly, Adimab, Incyte, Hanmi and others, plus recent partnerships with Ascentage Pharma and Spero Therapeutics, creating multiple entry points for co-development, licensing or distribution deals across oncology and biopharma-adjacent spaces.

Robust oncology portfolio A strong and growing cancer drug pipeline with approved products TYVYT, BYVASDA, SULINNO and HALPRYZA, plus a substantial late-stage and preclinical pipeline, offering multiple opportunities for in-licensing, co-commercialization or strategic partnerships to accelerate market access.

Global quality footprint Certified production platforms compliant with cGMP standards across NMPA, FDA and EMA, with GMP-audited facilities, enabling risk-mitigated manufacturing collaborations, tolling arrangements, and supply agreements for international markets.

Scale and reach Significant revenue scale and international market presence evidenced by listing on the HK Main Board and a revenue range in the billion-dollar bracket, suggesting capacity for large, multi-program deals and global distribution partnerships.

High-value opportunities Recent high-profile deals and trial progress in ADCs and multi-specifics (e.g., IBI355, DLL3-targeting programs, IBI363) indicate momentum in high-margin, differentiated modalities suitable for co-development, milestone-rich collaborations and strategic licensing with big pharma.